Gold Prices Rise as Hormuz Tensions Fuel Inflation Risks 
Indian Stocks Fall as RBI Hikes Rates to 5.50% 
US Dollar Hits 18-Month High as Fed Signals More Rate Hikes 
Fed Minutes Signal Another Rate Hike by Year-End 
Wall Street Falls as Fed Minutes Signal Another Rate Hike 
Asian Currencies Mixed as Yen Weakens, Dollar Holds Firm 
Bangladesh GDP Growth Accelerates to 4.6% on Industrial Rebound 
RBI Raises Repo Rate to 5.50% in Hawkish Shift on Inflation Risks 
Australia Consumer Confidence Plunges as RBA Rate Hike Hits Households 
US-Led Coalition Targets Global Factory Overcapacity 
Dollar Near 18-Month High as Euro, Yen and Pound Weaken 
Japan Real Wages Rise 1.5%, Supporting BOJ Rate Hikes 
European Stocks Fall as Oil Rises Ahead of Fed Minutes 
S&P 500 Hits Record High as AI Rally Lifts Wall Street 
UK House Prices Flat in September as Mortgage Rates Weigh 
Crypto Market Selloff Wipes Out $100B as Bitcoin Falls Below $83K 
Gold Prices Rise as Dollar Weakens, Treasury Yields Ease 
Add as a preferred source on Google
China has approved Eli Lilly’s Kisunla, marking another milestone in global efforts to address Alzheimer’s disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a unique dosing approach and new hope for managing the disease.
China Approves Kisunla as a New Alzheimer's Treatment Option
After Eisai and Biogen's Leqembi were approved in January, Eli Lilly said late Tuesday that their treatment for early Alzheimer's has been approved by China's medical authorities, giving patients another alternative, Reuters reports.
According to a statement from Lilly, the medication, which is marketed under the trade name Kisunla, has been approved in four key markets: the US, Japan, and the UK. The latest addition to this list is China.
In the same way as Leqembi removes beta-amyloid from the brain, Lilly's Kisunla does the same.
Kisunla Shows Promising Results in Cognitive Decline
Kisunla shown a 29% reduction in the development of cognitive impairments as compared to a placebo in a large, late-stage experiment. Although most occurrences were moderate, it did induce brain edema in approximately 25% of patients and brain bleeding in approximately 33%.
In the United States, the prescribing label for Kisunla bears the FDA's most severe "boxed" safety warning, which, like Leqembi, warns of the possibility of fatal brain enlargement and hemorrhage.
Gradual Dosing and Finite Treatment Benefit Kisunla Users
However, the business reported that the number of patients having potentially significant brain swelling was reduced when Kisunla was started on a more gradual dose schedule.
Another advantage of Kisunla over Leqembi is its finite dosage, which lets patients discontinue treatment once brain scans reveal no more amyloid plaques.
The medicines authority of the European Union is presently evaluating the treatment. In July, the body decided against using Leqembi because the potential for severe brain swelling was not worth the minimal benefit in preventing cognitive loss, Investing.com shares.
Alzheimer’s Drives Majority of Dementia Cases Globally
The World Health Organization reports that between sixty percent and seventy percent of dementia cases are caused by Alzheimer's disease.
